259 related articles for article (PubMed ID: 29520657)
21. Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients.
Righi S; Pileri S; Agostinelli C; Bacci F; Spagnolo S; Sabattini E
Hum Pathol; 2017 Jan; 59():94-101. PubMed ID: 27720733
[TBL] [Abstract][Full Text] [Related]
22. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
23. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
24. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma.
Hsiao SC; Cortada IR; Colomo L; Ye H; Liu H; Kuo SY; Lin SH; Chang ST; Kuo TU; Campo E; Chuang SS
Histopathology; 2012 Oct; 61(4):685-93. PubMed ID: 22642745
[TBL] [Abstract][Full Text] [Related]
25. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
26. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
[TBL] [Abstract][Full Text] [Related]
28. Combined molecular diagnosis of B-cell lymphomas with t(11;14)(q13;q32) or t(14;18)(q32;q21) using multiplex- and long distance inverse-polymerase chain reaction.
Vieira L; Martinho A; Antunes O; Silva E; Ambrósio AP; Geraldes MC; Nascimento R; Silva C; Pereira JM; Júnior EC; Jordan P
Diagn Mol Pathol; 2008 Jun; 17(2):73-81. PubMed ID: 18382373
[TBL] [Abstract][Full Text] [Related]
29. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma.
Welzel N; Le T; Marculescu R; Mitterbauer G; Chott A; Pott C; Kneba M; Du MQ; Kusec R; Drach J; Raderer M; Mannhalter C; Lechner K; Nadel B; Jaeger U
Cancer Res; 2001 Feb; 61(4):1629-36. PubMed ID: 11245476
[TBL] [Abstract][Full Text] [Related]
30. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.
Salaverria I; Royo C; Carvajal-Cuenca A; Clot G; Navarro A; Valera A; Song JY; Woroniecka R; Rymkiewicz G; Klapper W; Hartmann EM; Sujobert P; Wlodarska I; Ferry JA; Gaulard P; Ott G; Rosenwald A; Lopez-Guillermo A; Quintanilla-Martinez L; Harris NL; Jaffe ES; Siebert R; Campo E; Beà S
Blood; 2013 Feb; 121(8):1394-402. PubMed ID: 23255553
[TBL] [Abstract][Full Text] [Related]
31. SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.
Yang W; Wang Y; Yu Z; Li Z; An G; Liu W; Lv R; Ma L; Yi S; Qiu L
Int J Hematol; 2017 Aug; 106(2):212-220. PubMed ID: 28429312
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
33. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas.
Hsi AC; Hurley MY; Lee SJ; Rosman IS; Pang X; Gru A; Schaffer A
J Cutan Pathol; 2016 Apr; 43(4):354-61. PubMed ID: 26762898
[TBL] [Abstract][Full Text] [Related]
35. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
[TBL] [Abstract][Full Text] [Related]
36. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract][Full Text] [Related]
37. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
38. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
Brizova H; Kalinova M; Krskova L; Mrhalova M; Kodet R
Int J Cancer; 2008 Dec; 123(12):2865-70. PubMed ID: 18798551
[TBL] [Abstract][Full Text] [Related]
39. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
40. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]